Erasca, Inc. (ERAS) Research
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Market snapshot
- Symbol
- ERAS
- Price
- $13.67
- Day change
- -2.22%
- Market cap
- $4.3B
- P/E ratio
- -15.02x
- 52-week range
- 1.21-24.28
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $17.50
Peer companies
Recent insider activity
- Garner Ebun — M-Exempt (80000 shares) on 2026-04-01
- Garner Ebun — M-Exempt (80000 shares) on 2026-04-01
- Garner Ebun — S-Sale (80000 shares) on 2026-04-01
- Morris Shannon — M-Exempt (20000 shares) on 2025-03-04
- Morris Shannon — M-Exempt (20000 shares) on 2026-03-04
Open Erasca, Inc. (ERAS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.